JP2022512843A - スフィンゴシンキナーゼ１とその融合タンパク質およびその使用 - Google Patents

スフィンゴシンキナーゼ１とその融合タンパク質およびその使用 Download PDF

Info

Publication number
JP2022512843A
JP2022512843A JP2021523243A JP2021523243A JP2022512843A JP 2022512843 A JP2022512843 A JP 2022512843A JP 2021523243 A JP2021523243 A JP 2021523243A JP 2021523243 A JP2021523243 A JP 2021523243A JP 2022512843 A JP2022512843 A JP 2022512843A
Authority
JP
Japan
Prior art keywords
protein
acid sequence
amino acid
expression construct
protein drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512843A5 (https=
JPWO2020082950A5 (https=
Inventor
段海峰
解晶
胡顕文
弓景波
薛冰華
張群偉
肖秀孝
崔美蘭
▲パン▼如梦
王瑞
于▲ティン▼▲ティン▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING SHUANGYIN BIOTECHNOLOGY CO. LTD.
Original Assignee
BEIJING SHUANGYIN BIOTECHNOLOGY CO. LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING SHUANGYIN BIOTECHNOLOGY CO. LTD. filed Critical BEIJING SHUANGYIN BIOTECHNOLOGY CO. LTD.
Publication of JP2022512843A publication Critical patent/JP2022512843A/ja
Publication of JP2022512843A5 publication Critical patent/JP2022512843A5/ja
Publication of JPWO2020082950A5 publication Critical patent/JPWO2020082950A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01091—Sphinganine kinase (2.7.1.91)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021523243A 2018-10-21 2019-09-20 スフィンゴシンキナーゼ１とその融合タンパク質およびその使用 Pending JP2022512843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811225720.2A CN109355269B (zh) 2018-10-21 2018-10-21 鞘氨醇激酶1及其融合蛋白及其用途
CN201811225720.2 2018-10-21
PCT/CN2019/107091 WO2020082950A1 (zh) 2018-10-21 2019-09-20 鞘氨醇激酶1及其融合蛋白及其用途

Publications (3)

Publication Number Publication Date
JP2022512843A true JP2022512843A (ja) 2022-02-07
JP2022512843A5 JP2022512843A5 (https=) 2023-04-05
JPWO2020082950A5 JPWO2020082950A5 (https=) 2023-04-05

Family

ID=65345959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523243A Pending JP2022512843A (ja) 2018-10-21 2019-09-20 スフィンゴシンキナーゼ１とその融合タンパク質およびその使用

Country Status (4)

Country Link
US (1) US20210388326A1 (https=)
JP (1) JP2022512843A (https=)
CN (1) CN109355269B (https=)
WO (1) WO2020082950A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途
CN111303298B (zh) * 2020-02-19 2023-03-21 李瑛� 含有磷酸酶的融合蛋白及其产品和应用
CN112143705B (zh) * 2020-09-23 2022-09-06 北京华奥玄德生物医药科技有限公司 一种双基因修饰的干细胞及其用途
CN114762724A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpWEch蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN114762723A (zh) * 2020-12-31 2022-07-19 吴伯骥 HrpZpst蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用
CN112675293A (zh) * 2020-12-31 2021-04-20 吴伯骥 HrpNEcb蛋白在识别激活多类受体和/或膜蛋白及其信号通路的制药中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512072A (ja) * 1999-10-28 2003-04-02 ワーナー−ランバート・カンパニー ヒトスフィンゴシンキナーゼ遺伝子
JP2004510741A (ja) * 2000-10-05 2004-04-08 ノバルティス　アクチエンゲゼルシャフト スフィンゴシンキナーゼをコードするポリヌクレオチドの投与による血管形成の誘発
WO2014135984A2 (en) * 2013-03-07 2014-09-12 Recopharma Ab Glycosylated mucin-immunoglobulin fusion protein coated device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
JP6324137B2 (ja) * 2014-03-24 2018-05-16 ジヤトコ株式会社 シール機構付き車両用無段変速機
CN106279430B (zh) * 2015-06-30 2017-11-28 安源医药科技（上海）有限公司 Exendin‑4类似物融合蛋白及其制备方法和用途
CN106432511A (zh) * 2016-09-29 2017-02-22 上海凯茂生物医药有限公司 GLP‑1类似物‑Fc融合蛋白及其制备方法和用途
CN107875398B (zh) * 2017-09-27 2021-03-23 浙江大学 一种抗体偶联药物的制备方法、抗体偶联药物及应用
CN109355269B (zh) * 2018-10-21 2020-03-24 北京双因生物科技有限公司 鞘氨醇激酶1及其融合蛋白及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512072A (ja) * 1999-10-28 2003-04-02 ワーナー−ランバート・カンパニー ヒトスフィンゴシンキナーゼ遺伝子
JP2004510741A (ja) * 2000-10-05 2004-04-08 ノバルティス　アクチエンゲゼルシャフト スフィンゴシンキナーゼをコードするポリヌクレオチドの投与による血管形成の誘発
WO2014135984A2 (en) * 2013-03-07 2014-09-12 Recopharma Ab Glycosylated mucin-immunoglobulin fusion protein coated device

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADV DRUG DELIV REV., vol. 65, no. 10, JPN6022045370, 2013, pages 1357 - 1369, ISSN: 0005082704 *
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 518, JPN6022016641, 2012, pages 23 - 30, ISSN: 0004910958 *
BIOCONJUGATE CHEM., vol. 26, JPN6022045366, 2015, pages 1753 - 1758, ISSN: 0005082702 *
DIABETOLOGIA, vol. 50, JPN6022045372, 2007, pages 891 - 900, ISSN: 0005082705 *
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, JPN6022045367, 2015, pages 136 - 143, ISSN: 0005082703 *
THE FASEB JOURNAL, vol. 27, JPN6022016640, 2013, pages 4294 - 4304, ISSN: 0004910959 *

Also Published As

Publication number Publication date
US20210388326A1 (en) 2021-12-16
CN109355269A (zh) 2019-02-19
CN109355269B (zh) 2020-03-24
WO2020082950A1 (zh) 2020-04-30

Similar Documents

Publication Publication Date Title
JP2022512843A (ja) スフィンゴシンキナーゼ１とその融合タンパク質およびその使用
US8926972B2 (en) Anti-angiogenesis fusion proteins
US11752173B2 (en) FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
BR112019017001A2 (pt) composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo.
US20190352373A1 (en) TGF-ß DECOY RECEPTOR
CA2311681A1 (en) Human interferon-epsilon: a type i interferon
TW201420606A (zh) 同源二聚體蛋白
JP2018518946A (ja) アンジェルマン症候群の遺伝子治療法のための組み換えｕｂｅ３ａ遺伝子
US20170081387A1 (en) Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof
CN119604523A (zh) 正交gpc3嵌合抗原受体t细胞
JP7282899B2 (ja) 線維芽細胞成長因子２１変異体、その融合タンパク質とその使用
CN104974262B (zh) 重组双功能融合蛋白及其制法和用途
KR20220131529A (ko) 변경된 icd stat 신호전달을 갖는 cd122
US20230076768A1 (en) IL2 Orthologs and Methods of Use
JP2024507321A (ja) ヒトｇｌｐ－１ポリペプチド変異体及びその応用
US12589141B2 (en) DNA vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
CN114149498B (zh) 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149499B (zh) 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
CN107298714A (zh) 一种双靶标融合蛋白及其制备方法和用途
Wu et al. Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy
CN118620086B (zh) 一种治疗糖尿病的融合蛋白及其应用
KR20230166078A (ko) Il-15 융합 단백질 및 이를 제조 및 사용하는 방법
US20230287135A1 (en) Multifunctional antibody, preparation for same, and uses thereof
WO2024067776A1 (zh) 核酸构建体及其用途
CN120005036A (zh) 用于老年相关性黄斑变性的治疗的基因治疗药物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230123

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613